Patterns in blood pressure medication use in US incident dialysis patients over the first 6 months

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  St Peter, Wendy L ^a,b   Sozio, Stephen M ^c,d   Shafi, Tariq ^c,d   Ephraim, Patti L ^d,e   Luly, Jason ^c   McDermott, Aidan ^e   Bandeen Roche, Karen ^e   Meyer, Klemens B ^f   Crews, Deidra C ^c,d   Scialla, Julia J ^g   Miskulin, Dana C ^f   Tangri, Navdeep ^h   Jaar, Bernard G ^c,d,e,i   Michels, Wieneke M ^c,d,j   Wu, Albert W ^c,e   Ebony Boulware, L ^c,d,e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ NEPHROLOGY CENTER OF MARYLAND   (United States)

^j ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

Blood pressure medication; Dialysis; Medication use patterns

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARVEDILOL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; HYDRALAZINE; IRBESARTAN; LABETALOL; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; MINOXIDIL; OLMESARTAN; QUINAPRIL; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; ETHNICITY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PRESCRIPTION; TREATMENT DURATION; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; CAUSALITY; COMORBIDITY; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS; PREVALENCE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 84887293802     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-249     Document Type: Article

References (22)

1. U.S. Renal Data System, USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2012 2012
2. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Agarwal R, Sinha AD, Hypertension 2009 53 860 866 10.1161/HYPERTENSIONAHA.108.128116 19273737
3. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Heerspink HJ, Ninomiya T, Zoungas S, et al. Lancet 2009 373 1009 1015 10.1016/S0140-6736(09)60212-9 19249092
4. Higher survival rates of chronic hemodialysis patients on anti-hypertensive drugs. Iseki K, Shoji T, Nakai S, Watanabe Y, Akiba T, Tsubakihara Y, Nephron Clin Pract 2009 113 183 c190 10.1159/000232600 19672117
5. Beta-blocker prescription and outcomes in hemodialysis patients from the Japan Dialysis Outcomes and Practice Patterns Study. Nakao K, Makino H, Morita S, et al. Nephron Clin Pract 2009 113 132 c139 10.1159/000232593 19672110
6. beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL, Arch Intern Med 2004 164 2465 2471 10.1001/archinte.164. 22.2465 15596637 (Pubitemid 39628074)
7. Prescription of antihypertensive agents to haemodialysis patients: time trends and associations with patient characteristics, country and survival in the DOPPS. Lopes AA, Bragg-Gresham JL, Ramirez SP, et al. Nephrol Dial Transplant 2009 24 2809 2816 10.1093/ndt/gfp212 19443648
8. Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. Griffith TF, Chua BS, Allen AS, Klassen PS, Reddan DN, Szczech LA, Am J Kidney Dis 2003 42 1260 1269 10.1053/j.ajkd.2003.08.028 14655199 (Pubitemid 37486771)
9. Cardiac medications and their association with cardiovascular events in incident dialysis patients: cause or effect? Ishani A, Herzog CA, Collins AJ, Foley RN, Kidney Int 2004 65 1017 1025 10.1111/j.1523-1755.2004.00473.x 14871422 (Pubitemid 38251078)
10. Calcium channel blocker use and mortality among patients with end-stage renal disease. Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C, Kidney Int 2002 61 2157 2164 10.1046/j.1523-1755.2002.00355.x 12028456 (Pubitemid 34539333)
11. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Foley RN, Herzog CA, Collins AJ, Kidney Int 2002 62 1784 1790 10.1046/j.1523-1755.2002.00636.x 12371980 (Pubitemid 35286287)
12. Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider. Manley HJ, Garvin CG, Drayer DK, et al. Nephrol Dial Transplant 2004 19 1842 1848 10.1093/ndt/gfh280 15128886 (Pubitemid 38961397)
13. Patterns of antihypertensive medication use in hemodialysis patients. Rahman M, Griffin V, Am J Health Syst Pharm 2004 61 1473 1478 15332695 (Pubitemid 39481419)
14. Geographic variation in cardioprotective antihypertensive medication usage in dialysis patients. Wetmore JB, Mahnken JD, Mukhopadhyay P, et al. Am J Kidney Dis 2011 58 73 83 10.1053/j.ajkd.2011.02.387 21621889
15. Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D. Frankenfield DL, Weinhandl ED, Powers CA, Howell BL, Herzog CA, St.Peter WL, Am J Kidney Dis 2012 59 670 681 10.1053/j.ajkd.2011. 10.047 22206743
16. Patterns of cardioprotective medication prescription in incident hemodialysis patients. Sood MM, Battistella M, Lok CE, Int Urol Nephrol 2009 41 1021 1027 10.1007/s11255-009-9606-1 19653115
17. Comparative effectiveness studies to improve clinical outcomes in end stage renal disease: the DEcIDE patient outcomes in end stage renal disease study. Boulware EL, Tangri N, Ephraim PL, et al. BMC Nephrol 2012 13 167 10.1186/1471-2369-13-167 23217181
18. Preservation of residual renal function in dialysis patients. Thomas J, Teitelbaum I, Adv Perit Dial 2011 27 112 117 22073841
19. Predictors of the rate of decline of residual renal function in incident dialysis patients. Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT, Kidney Int 2002 62 1046 1053 10.1046/j.1523-1755.2002.00505.x 12164889 (Pubitemid 35316736)
20. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Medcalf JF, Harris KP, Walls J, Kidney Int 2001 59 1128 1133 10.1046/j.1523-1755.2001.0590031128.x 11231370 (Pubitemid 32206877)
21. Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Bragg-Gresham JL, Fissell RB, Mason NA, et al. Am J Kidney Dis 2007 49 426 431 10.1053/j.ajkd.2006.12.012 17336704
22. Dilated cardiomyopathy in dialysis patients-beneficial effects of carvedilol: a double-blind, placebo-controlled trial. Cice G, Ferrara L, Di Benedetto A, et al. J Am Coll Cardiol 2001 37 407 411 10.1016/S0735-1097(00) 01158-X 11216954